Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease

What Was Tested

The paper reports a study of Somatostatin and Lanreotide, published as a randomized controlled trial.

There are limited therapeutic options to slow the progression of autosomal dominant polycystic kidney disease (ADPKD).

The design is an open randomized controlled trial and measurement of their primary end point does not begin at randomization.

Who Took Part

The abstract describes 300 individuals taking part.

By PubMed's age tags, the people studied were teenagers, young adults, adults and middle-aged adults, both men and women.

Magnetic resonance imaging will be performed for assessment of kidney and liver volume.

How the Study Was Run

The researchers set it up as a randomized and multicenter study.

The individuals were allocated by chance, so the Somatostatin group and the comparison group should start out alike.

Running at several centres spread the Somatostatin study over different clinics and patient groups.

The DIPAK 1 Study is an investigator-driven, randomized, multicenter, controlled, clinical trial.

Blood and urine will be collected and questionnaires will be filled in following a fixed scheme.

What Was Measured

The design is an open randomized controlled trial and measurement of their primary end point does not begin at randomization.

The subject headings attached to it are Antineoplastic Agents, Disease Progression, Glomerular Filtration Rate, Peptides, Cyclic, Polycystic Kidney, Autosomal Dominant, Quality of Life and Somatostatin.

Author keywords: Polycystic kidney disease (PKD), cyst progression, disease trajectory, glomerular filtration rate (GFR), kidney volume and quality of life (QoL).

What This Means in Plain Language

The paper is a randomized and multicenter study of Somatostatin and Lanreotide in 300 individuals.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (American journal of kidney diseases : the official journal of the National Kidney Foundation), a journal based in United States.

More context: the Somatostatin compound page and the Lanreotide compound page, all human trials.